Published December 12. 2012 4:00AM
Amarin Corp. plc said Tuesday that it has added another supplier for the active ingredient in its heart medication Vascepa.
Amarin, with research headquarters in Groton, said a consortium of companies led by Canada-based Slanmhor Pharmaceuticals Inc. will be its fourth supplier of highly purified omega-3 fish oil.
Amarin's stock price immediately tanked 10 percent on the news, as investors expecting to hear encouraging words about the company's application to have Vascepa declared a new chemical entity were disappointed, according to TheMotleyFool.com investment website.
"Today's announcement simply wasn't enough to get investors' minds off that pesky NCE status," the website said.